Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy.

• Status: Not yet recruiting
• Trial end date: 2023-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the possible antifibrotic effect of zinc sulphate in chronic HCV patient receiving direct acting anti-viral therapy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University

Criteria

Inclusion Criteria:

• • Patients with fibrosis stage (F1&F2) post chronic HCV infection.

• Age > 18 and < 65 years.

Exclusion Criteria:

• Patients with prior history of liver transplantation.

• Patients with prior history of hepatocellular carcinoma.

• Patients coinfected with HIV or HBV.

• Patients with any malignancies.

• Pregnant and lactating women.